PD-L1 blockade immunotherapy rewires cancer emergency myelopoiesis
A. Boumpas, A. S. Papaioannou, P. Bousounis, M. Grigoriou, V. Bergo, I. Papafragkos, A. Tasis, M. Iskas, L. Boon, M. Makridakis, A. Vlahou, E. Gavriilaki, A. Hatzioannou, I. Mitroulis, E. Trompouki, P. Verginis
This study shows PD-L1 blockade in tumor-bearing mice targets bone marrow HSPCs, reprograms their transcriptome toward inflammation, and reduces myeloid-derived suppressor cells.
bioRxiv · Dec 20, 2023 · PreprintImmunology